We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Novel Biomarkers Predict CV Events in Type 2 Diabetes

By LabMedica International staff writers
Posted on 20 Sep 2018
Print article
Image: High magnification micrograph of senile cardiac amyloidosis from an autopsy specimen (Photo courtesy of Nephron).
Image: High magnification micrograph of senile cardiac amyloidosis from an autopsy specimen (Photo courtesy of Nephron).
Cardiovascular disease generally refers to conditions that involve narrowed or blocked blood vessels that can lead to a heart attack, chest pain (angina) or stroke. Cardiovascular disease (CVD) risk prediction represents an increasing clinical challenge in the treatment of diabetes.

A panel of vascular imaging, functional assessments, and biomarkers reflecting different disease mechanisms has been used to identify clinically useful markers of risk for cardiovascular (CV) events in subjects with type 2 diabetes (T2D) with or without manifest CVD.

A team of scientists led by those at the University of Exeter (Exeter, UK) recruited 936 subjects with T2D at four European centers. Carotid intima-media thickness and plaque area, ankle-brachial pressure index, arterial stiffness, endothelial function, and circulating biomarkers were analyzed at baseline, and CV events were monitored during a three-year follow-up period.

The investigators reported that the CV event rate in 440 subjects with T2D was statistically higher in those with than in those 496 without manifest CVD at baseline (5.53 versus 2.15/100 life-years). New CV events in subjects with T2D with manifest CVD were associated with higher baseline levels of inflammatory biomarkers such as interleukin 6, chemokine ligand 3, pentraxin 3, and high sensitivity C-reactive protein (hs-CRP) and endothelial mitogens represented by, hepatocyte growth factor and vascular endothelial growth factor A. However, CV events in subjects with T2D without manifest CVD were associated with more severe baseline atherosclerosis (median carotid plaque area 34.5 mm2 versus 19.5 mm2. Conventional risk factors, as well as measurements of arterial stiffness and endothelial reactivity, were not associated with CV events.

The authors concluded that their observations demonstrate that markers of inflammation and endothelial stress reflect CV risk in subjects with T2D with manifest CVD, whereas the risk for CV events in subjects with T2D without manifest CVD is primarily related to the severity of atherosclerosis. The study was published on July 6, 2018, in the journal Diabetes Care.

Related Links:
University of Exeter

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Molecular Diagnostics

view channel
Image: A network of inflammatory molecules may act as biomarker for risk of future cerebrovascular disease (Photo courtesy of 123RF)

Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease

Cerebral small vessel disease is a common cause of stroke and cognitive decline, particularly in the elderly. Presently, assessing the risk for cerebral vascular diseases involves using a mix of diagnostic... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The Aperio GT 450 DX has received US FDA 510(k) clearance (Photo courtesy of Leica Biosystems)

Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization

Digital pathology is rapidly becoming a key aspect of modern healthcare, transforming the practice of pathology as laboratories worldwide adopt this advanced technology. Digital pathology systems allow... Read more